NEW YORK (GenomeWeb) – Myriad Genetics announced today that it has entered into a strategic research collaboration with Tesaro and Merck. The two pharmaceutical companies will use Myriad's myChoice HRD companion diagnostic in a clinical trial of an investigational drug therapy combining Tesaro's PARP inhibitor, niraparib, with Merck's anti-PD-1 therapy, pembrolizumab (commercially sold as Keytruda).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.